Trials / Terminated
TerminatedNCT00387192
A Study With OPTIVATE® in People With Von Willebrand Disease
An Open Multi-centre Study in Patients With Von Willebrand Disease to Investigate the Pharmacokinetics, Efficacy and Safety of OPTIVATE®, a High Purity, Dual Inactivated Factor VIII and Von Willebrand Factor Concentrate
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 26 (estimated)
- Sponsor
- Bio Products Laboratory · Academic / Other
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of the study is to assess the pharmacokinetics of OPTIVATE® after a single dose of 80 IU/kg VWF:RCo. The secondary objectives of the study are to assess efficacy and safety of OPTIVATE® in long-term use over at least 12 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Optivate | Plasma-derived Factor VIII |
Timeline
- Start date
- 2006-11-01
- Completion
- 2008-09-01
- First posted
- 2006-10-12
- Last updated
- 2010-03-03
Locations
4 sites across 2 countries: Israel, United Kingdom
Source: ClinicalTrials.gov record NCT00387192. Inclusion in this directory is not an endorsement.